Paper40833332
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.
Mazzaschi G and 21 others. Immunotherapy, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy. Papers, record 40833332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40833332
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy | Major topic |
| Pleural Neoplasms | Major topic |
| Mesothelioma | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| Prognosis | |
| Transcriptome | |
| Tumor Microenvironment | |
| Nivolumab | |
| Biomarkers, Tumor | |
| Ipilimumab | |
| Mesothelioma, Malignant |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25791825 | Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. | J Surg Res | 2015 | https://conductscience.org/library/papers/25791825 | PubMed |
| 2 | 33485464 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33485464 | PubMed |
| 3 | 33837910 | Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. | Clin Transl Oncol | 2021 | https://conductscience.org/library/papers/33837910 | PubMed |
| 4 | 36773602 | Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/36773602 | PubMed |
| 5 | 28777143 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. | Adv Anat Pathol | 2017 | https://conductscience.org/library/papers/28777143 | PubMed |
| 6 | 29203879 | QuPath: Open source software for digital pathology image analysis. | Sci Rep | 2017 | https://conductscience.org/library/papers/29203879 | PubMed |
| 7 | 16621962 | ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. | Blood | 2006 | https://conductscience.org/library/papers/16621962 | PubMed |
| 8 | 26694968 | CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. | J Exp Med | 2016 | https://conductscience.org/library/papers/26694968 | PubMed |
| 9 | 31924474 | Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells. | Immunity | 2020 | https://conductscience.org/library/papers/31924474 | PubMed |
| 10 | 30642544 | The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. | Lung Cancer | 2019 | https://conductscience.org/library/papers/30642544 | PubMed |
| 11 | 12478000 | Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. | Am J Clin Oncol | 2002 | https://conductscience.org/library/papers/12478000 | PubMed |
| 12 | 26155428 | The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. | Oncoimmunology | 2015 | https://conductscience.org/library/papers/26155428 | PubMed |
| 13 | 34656227 | Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34656227 | PubMed |
| 14 | 38396241 | Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/38396241 | PubMed |
| 15 | 30909496 | MYC Oncogene Contributions to Release of Cell Cycle Brakes. | Genes (Basel) | 2019 | https://conductscience.org/library/papers/30909496 | PubMed |
| 16 | 34910940 | Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox. | Immunity | 2021 | https://conductscience.org/library/papers/34910940 | PubMed |
| 17 | 38036250 | Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/38036250 | PubMed |
| 18 | 33637530 | Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. | Sci Adv | 2021 | https://conductscience.org/library/papers/33637530 | PubMed |
| 19 | 39814199 | A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. | Ann Oncol | 2025 | https://conductscience.org/library/papers/39814199 | PubMed |
| 20 | 32676358 | Clinical significance of histologic subtyping of malignant pleural mesothelioma. | Transl Lung Cancer Res | 2020 | https://conductscience.org/library/papers/32676358 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41826598 | Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41826598 | PubMed |
| 41767494 | Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41767494 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD14 | 929 | PubTator's text mining | https://conductscience.org/library/genes/929 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| GZMB | 3002 | PubTator's text mining | https://conductscience.org/library/genes/3002 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| ULBP2 | 80328 | PubTator's text mining | https://conductscience.org/library/genes/80328 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40833332
GET https://conductscience.org/api/papers/v1/40833332/authors?page=2